LBA36 Final Analysis of RATIONALE-301: Randomized, Phase III Study of Tislelizumab Versus Sorafenib As First-Line Treatment for Unresectable Hepatocellular Carcinoma
Annals of Oncology（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined